Splenic volume differentiates complicated and non-complicated celiac disease

Abstract

Background

Studies in small groups of patients indicated that splenic volume (SV) may be decreased in patients with celiac disease (CD), refractory CD (RCD) type II and enteropathy-associated T-cell lymphoma (EATL).

Objective

The objective of this article is to evaluate SV in a large cohort of uncomplicated CD, RCD II and EATL patients and healthy controls.

Methods

The retrospective cohort consisted of 77 uncomplicated CD (of whom 39 in remission), 29 RCD II, 24 EATL and 12 patients with both RCD II and EATL. The control group included 149 healthy living kidney donors. SV was determined on computed tomography.

Results

The median SV in the uncomplicated CD group was significantly larger than in controls (202 cm³ (interquartile range (IQR): 154–275) versus 183 cm³ (IQR: 140–232), p = 0.02). After correction for body surface area, age and gender, the ratio of SV in uncomplicated CD versus controls was 1.28 (95% confidence interval: 1.20–1.36; p < 0.001). The median SV in RCD II patients (118 cm³ (IQR 83–181)) was smaller than the median SV in the control group (p < 0.001).

Conclusion

This study demonstrates large inter-individual variation in SV. SV is enlarged in uncomplicated CD. The small SV in RCD II may be of clinical relevance considering the immune-compromised status of these patients.

Keywords

Celiac disease refractory celiac disease enteropathy-associated T-cell lymphoma splenic volume computed tomography spleen

Introduction

Celiac disease (CD) is a chronic autoimmune-mediated enteropathy of the small bowel, caused by exposure to dietary gluten in genetically pre-disposed individuals resulting in villous atrophy.¹ The prevalence of CD is 0.5%–1% in Western countries, North Africa, the Middle East and the Indian subcontinent.^1–3 The only accepted treatment in CD is a life-long gluten-free diet (GFD). In less than 1% of CD patients, villous atrophy persists despite a GFD.⁴ After exclusion of other, mostly rare, diseases such as collagenous sprue, common variable immunodeficiency, Giardia lamblia and autoimmune enteropathy, these patients are diagnosed with refractory CD (RCD).⁵ RCD can be divided in two types based on the absence (type I) or presence (type II) of an intraepithelial lymphocyte population with an aberrant phenotype.⁶ This phenotype is characterized by lack of surface CD3 (sCD3) expression, but presence of intracellular CD3 complexes (iCD3). RCD II is now considered as a precursor of enteropathy-associated T-cell lymphoma (EATL), a lymphoma with a poor prognosis.^7,8

Splenic atrophy in CD patients has already been reported in a necropsy study in the 1970s.⁹ Impairment of splenic function in CD patients has been recognized over the years that was not associated with development of malignant disease.^10–15 Similarly, functional hyposplenism can also be found in other diseases such as sickle cell disease and inflammatory bowel disease.^16,17

In a pilot study, we observed that patients with RCD II and EATL appeared to have a smaller spleen on computed tomography (CT) than uncomplicated CD patients.¹⁸ Other studies involving small numbers of individuals suggested a small spleen in uncomplicated CD patients as well.^19,20

The aim of this study was to evaluate in a large patient cohort whether splenic volume (SV), as measured by CT, is different in subgroups of CD as compared with healthy controls.

Materials and methods

Patients

All CD, RCD II and EATL patients included in this study have been initially diagnosed with CD according to the United European Gastroenterology Week (UEGW) criteria.²¹ Indications for CT were assessment of abdominal complaints at diagnosis or follow-up of CD and/or (suspected) RCD II or EATL. Active CD was defined as Marsh III and/or positive serology for antibodies against tissue transglutaminase (TGA) type 2 and/or endomysium (EMA) six months before or after CT. CD in remission was defined as Marsh 0 or I and/or negative serology before or up to six months after CT. Patients were diagnosed with RCD II when other causes of villous atrophy had been excluded and more than 20% of the intra-epithelial lymphocytes showed an aberrant phenotype (sCD3⁻ iCD3⁺) or when ulcerative jejunitis in CD was diagnosed.⁵ The control group included healthy individuals who underwent screening for kidney donation.

Methods

This study was a retrospective study including complicated and uncomplicated CD patients and controls who underwent CT between 2000 and 2013. SV was calculated by two expert radiologists with special interest in CD and scored according to a standard formula: SV = 30 + 0.58 (length × width × height).²² Body surface area (BSA) was calculated by the formula of Du Bois and Du Bois including height and weight.²³

Statistical analysis

Differences in continuous variables between the different groups were analyzed using the Independent-Samples Kruskal–Wallis Test and the Independent-Samples Mann–Whitney U Test. For categorical variables we used the Pearson Chi-Square test. Differences in SV between the different groups were analyzed using both univariate and multivariate linear regression analysis. For the linear regression analysis, SV was transformed to a logarithmic scale because of the skewed distribution of this variable. The difference in means on the logarithmic scale was the ratio of geometric means after transforming the data back to the original scale. Multivariate linear regression analysis included the potential confounders age, gender and BSA up to one year before or after CT.^24,25 We carried out backward linear regression analysis with a p value for removal of 0.1. P values of less than 0.05 were considered to be statistically significant. All statistical analysis were performed using IBM SPSS Statistics Version 20.

This study was presented to the Medical Ethics Review committee of VU University Medical Center. They confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study and that an official approval of this study by the committee is not required.

Results

Initially, 322 individuals were included in the study. Of these individuals 31 were excluded because of positive CD antibodies together with Marsh 0, I or II (n = 13) or because of negative CD antibodies together with Marsh II or III (n = 18).

Ultimately, 291 individuals were included consisting of 149 healthy controls, 77 uncomplicated CD and 65 complicated CD patients, defined as RCD II and/or EATL. The uncomplicated CD group consisted of 38 patients with active CD and 39 patients with CD in remission. Median time between diagnosis of CD and CT in the CD in remission group was five years (interquartile range (IQR): 2–11), which is indicative for time using a GFD. The complicated CD group consisted of 29 RCD II patients, 24 EATL patients without history of RCD II and 12 patients with both RCD II and EATL. Baseline characteristics are summarized in Table 1.

Table 1.

Baseline characteristics

	Total	Controls	CD	RCD II	EATL	Both RCDII and EATL	Overall p value
Patients (n)	291	149	77	29	24	12	–
Gender (M/F) (%)	130/161 (45%/55%)	72/77 (48%/52%)	23/54 (30%/70%)	16/13 (55%/45%)	14/10 (58%/42%)	5/7 (42%/58%)	0.03
Median age at CT (years) (range)	57 (18–88)	55 (26–84)	51 (18–86)	64 (44–88)	64 (51–73)	63 (56–68)	<0.001
Median BSA (m²) (range) Missing BSA data (n) (%)	1.84 (1.32–2.41) 23 (8%)	1.93 (1.48–2.41) 3 (2%)	1.80 (1.32–2.36) 13 (17%)	1.68 (1.42–2.00) 4 (14%)	1.83 (1.48–2.17) 2 (8%)	1.70 (1.50–2.14) 1 (8%)	<0.001
Median splenic volume (cm³) (IQR)	185 (136–245)	183 (140–232)	202 (154–275)	118 (83–181)	195 (163–259)	144 (129–238)	<0.001

CD: celiac disease; RCD II: refractory celiac disease type II; EATL: enteropathy-associated T-cell lymphoma; M: male; F: female; CT: computed tomography; BSA: body surface area; IQR: interquartile range.

The median SV in the control group was 183 cm³ (IQR: 140–232), versus 202 cm³ (IQR: 154–275) in the uncomplicated CD group (p = 0.020), whereas in the complicated CD group a smaller median SV compared with controls of 162 cm³ (IQR: 114–210) was found (p = 0.026). Subdivision of the uncomplicated CD group showed a median SV of 223 cm³ (IQR: 168–328) in active CD and 192 cm³ (IQR: 143–253) in CD in remission (p = 0.196). Between these two CD subgroups, there was also no significant difference in age (p = 0.409), gender (p = 0.411) and BSA (p = 0.338). Subdivision of the complicated CD group showed a median spleen of 118 cm³ (IQR: 83–181) in RCD II, 195 cm³ in EATL (IQR: 163–259) and 144 cm³ (range: 54–310) in patients with both RCD II and EATL. A smaller spleen was found in RCD II patients without EATL compared both with controls and uncomplicated CD (both p < 0.001), as well as compared with EATL patients with or without RCD II (respectively p = 0.039 and p < 0.001). SV distribution is shown in Figure 1.

Figure 1.

Splenic volume (cm³) in different groups.

A multivariate linear regression analysis was subsequently used to analyze the relationship between SV and the different groups taking into account the potential confounders BSA, age at time of CT (years) and gender. Due to the small number of patients in the different complicated CD subgroups, only the three main groups: controls, uncomplicated CD and complicated CD were compared in this analysis. BSA, age and gender were all significantly related to the logarithmic transformed SV on univariate regression analysis (all p < 0.001), as showed in Table 2. Performing backward multivariate regression, the variables complicated CD and gender were removed from the model. The corrected ratio of geometric means of SV in uncomplicated CD versus controls equals 1.28 (95% confidence interval (CI) 1.20–1.36) (p = 0.001). Notably, both in univariate and multivariate analysis, BSA had the largest effect on SV (Tables 2 and 3). Performing the same backward analysis after dividing the uncomplicated CD group in active CD and CD in remission showed a significantly larger SV in both groups compared with controls with a ratio of 1.33 (CI 1.14–1.56), p < 0.001 and 1.23 (CI 1.03–1.45), p = 0.018, respectively. In this model, complicated CD and gender were also removed.

Table 2.

Univariate regression analysis: The relationship between splenic volume and other variables

	Unstandardized coefficients	95% CI	p value
Uncomplicated CD (uncomplicated CD vs control)	1.15	1.09–1.22	0.014
Complicated CD (complicated CD vs control)	0.82	0.77–0.88	0.004
Gender (female vs male)	0.80	0.76–0.84	<0.001
Age (years)	0.991	0.989–0.993	<0.001
BSA (m²)	2.23	1.97–2.54	<0.001

CD: celiac disease; BSA: body surface area; CI: confidence interval.

Table 3.

Multivariate regression analysis: The relationship between splenic volume and other variables

	Unstandardized coefficients	95% CI	p value
Uncomplicated CD (uncomplicated CD vs control)	1.28	1.20–1.36	<0.001
Complicated CD (complicated CD vs control)	^a	–	–
Gender (female vs male)	^a	–	–
Age (years)	0.994	0.992–0.996	0.002
BSA (m²)	2.46	2.17–2.78	<0.001

Removed from the model by performing backward analysis.

CD: celiac disease; BSA: body surface area; CI: confidence interval.

Discussion

This study demonstrated large inter-individual variation in SV and the strong positive correlation between BSA in SV as described before.^22,25 We observed a significantly larger SV in uncomplicated CD patients when compared with healthy controls, a difference that remained significant after correction for confounders. This is remarkable since both functional hyposplenism and splenic atrophy have been described in CD patients.^10–17

The observation of Trewby et al. that CD patients on a GFD for several years had a smaller spleen than CD patients who had just started a GFD was not confirmed in this large data set.¹⁹

RCD II patients, a condition seen as a precursor of EATL, were found to have a smaller SV compared both with controls and uncomplicated CD. This observation may be of clinical relevance considering that these patients are generally considered immune-compromised because of malnutrition, wasting and mucosal immune dysfunction.

The finding of a smaller SV of RCD II patients in the absence of EATL compared with EATL patients with or without RCD II could probably be the effect of the lymphoma since extraintestinal presentations of EATL are common in the spleen.²⁶

Since it has been reported that SV and splenic function are positively correlated with each other,²⁷ there might be a correlation between splenic function and celiac disease as well. Our finding that SV did not differ between active CD and CD in remission is remarkably since previous studies have highlighted that a GFD was effective in restoring splenic function, except in CD patients with other autoimmune disorders, RCD and EATL.^28,29 Splenic functions include phagocytosis of erythrocytes, recycling of iron, induction of adaptive immune responses and capture and removal of (encapsulated) pathogens.³⁰ The latter function is achieved by the combination of specific anatomical features together with highly adapted macrophages of the spleen.³¹ Therefore, splenic atrophy and thereby impairment of splenic function could lead to an increased risk of infection with encapsulated bacteria such as Steptococcus pneumoniae. Although it is known that CD patients have a higher risk of pneumonia compared both to CD patients vaccinated against streptococcal pneumonia and the general population, there is a low pneumococcal vaccination rate in CD patients.³²

As a consequence of impairment of splenic function, the risk of developing other auto-immune-mediated disease by T-regulatory cell depletion due to splenic dysfunction also increases.¹¹ It is interesting that a recent study showed that the prevalence of other immune-mediated disorders was high at CD diagnosis (20%) and increased during follow-up with more than half of the patients developing new immune-mediated diseases despite a GFD.³³ Splenic dysfunction can also lead to reduced platelet sequestration and defective removal of pits from erythrocytes. The first might induce thromboembolism, the latter an increase of circulating Howell-Jolly bodies and pitted red cells.^11,34

The most important strength of this study is the inclusion of a unique large group of both complicated and uncomplicated CD and healthy controls. Although the RCD II cohort is one of the largest known RCD II cohorts in the literature, it is still too small to correct SV for BSA, age and gender. Further research is necessary to evaluate splenic function both in uncomplicated and complicated CD and how this relates to SV.

Footnotes

Declaration of conflicting interests

None declared.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Castillo

Theethira

Leffler

. The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf) 2015; 3: 3–11.

Makharia

Mulder

Goh

. Issues associated with the emergence of coeliac disease in the Asia-Pacific region: A working party report of the World Gastroenterology Organization and the Asian Pacific Association of Gastroenterology. J Gastroenterol Hepatol 2014; 29: 666–677.

Green

Cellier

. Celiac disease. N Engl J Med 2007; 357: 1731–1743.

Nijeboer

van Wanrooij

Tack

. Update on the diagnosis and management of refractory coeliac disease. Gastroenterol Res Pract 2013; 2013: 518483–518483.

Van Gils

Nijeboer

van Wanrooij

. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579.

Mulder CJ, Wahab PJ, Moshaver B, et al. Refractory coeliac disease: A window between coeliac disease and enteropathy associated T cell lymphoma. Scand J Gastroenterol Suppl 2000: 32–37.

Al-Toma

Verbeek

Hadithi

. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: Retrospective evaluation of single-centre experience. Gut 2007; 56: 1373–1378.

Tack

Verbeek

Al-Toma

. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011; 17: 506–513.

Thompson

. Necropsy studies on adult coeliac disease. J Clin Pathol 1974; 27: 710–721.

10.

Harmon

Lee

. Splenic atrophy in celiac disease. Clin Gastroenterol Hepatol 2010; 8: A22–A22.

11.

Di Sabatino

Brunetti

Carnevale

. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318.

12.

Ferguson

Hutton

Maxwell

. Adult coeliac disease in hyposplenic patients. Lancet 1970; 1: 163–164.

13.

Corazza

Zoli

Di Sabatino

. A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 1999; 94: 391–397.

14.

O’Grady

Stevens

McCarthy

. Celiac disease: Does hyposplenism predispose to the development of malignant disease? Am J Gastroenterol 1985; 80: 27–29.

15.

Robertson

Swinson

Hall

. Coeliac disease, splenic function, and malignancy. Gut 1982; 23: 666–669.

16.

William

Thawani

Sae-Tia

. Hyposplenism: A comprehensive review. Part II: Clinical manifestations, diagnosis, and management. Hematology 2007; 12: 89–98.

17.

William

Corazza

. Hyposplenism: A comprehensive review. Part I: Basic concepts and causes. Hematology 2007; 12: 1–13.

18.

Mallant

Hadithi

Al-Toma

. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol 2007; 13: 1696–1700.

19.

Trewby

Chipping

Palmer

. Splenic atrophy in adult coeliac disease: Is it reversible? Gut 1981; 22: 628–632.

20.

Balaban

Popp

Lungu

. Ratio of spleen diameter to red blood cell distribution width: A novel indicator for celiac disease. Medicine (Baltimore) 2015; 94: e726–e726.

21.

When is a coeliac a coeliac? Report of a working group of the United European Gastroenterology Week in Amsterdam, 2001. Eur J Gastroenterol Hepatol 2001; 13: 1123–1128.

22.

Prassopoulos

Daskalogiannaki

Raissaki

. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 1997; 7: 246–248.

23.

Du Bois

. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989; 5: 303–311. discussion 312–313.

24.

Caglar

Alkoc

Uygur

. Determination of normal splenic volume in relation to age, gender and body habitus: A stereological study on computed tomography. Folia Morphol (Warsz) 2014; 73: 331–338.

25.

Linguraru

Sandberg

Jones

. Assessing splenomegaly: Automated volumetric analysis of the spleen. Acad Radiol 2013; 20: 675–684.

26.

Catassi

Bearzi

Holmes

. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005; 128(4 Suppl 1): S79–S86.

27.

Smart

Ryan

Holdworth

. Relationship between splenic size and splenic function. Gut 1978; 19: 56–59.

28.

Corazza

Frisoni

Vaira

. Effect of gluten-free diet on splenic hypofunction of adult coeliac disease. Gut 1983; 24: 228–230.

29.

Di Sabatino

Rosado

Cazzola

. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 2006; 4: 179–186.

30.

Mebius

Kraal

. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606–616.

31.

Kraal

. Cells in the marginal zone of the spleen. Int Rev Cytol 1992; 132: 31–74.

32.

Zingone

Abdul Sultan

Crooks

. The risk of community-acquired pneumonia among 9803 patients with coeliac disease compared to the general population: A cohort study. Aliment Pharmacol Ther 2016; 44: 57–67.

33.

Imperatore

Rispo

Capone

. Gluten-free diet does not influence the occurrence and the Th1/Th17-Th2 nature of immune-mediated diseases in patients with coeliac disease. Dig Liver Dis 2016; 48: 740–744.

34.

Lammers

de Porto

Bennink

. Hyposplenism: Comparison of different methods for determining splenic function. Am J Hematol 2012; 87: 484–489.